Figure 5

Increased NRP1 expression is associated with tumor progression and primary therapy failure. (a) Representative images of BPH and Gleason grade 3, 4 or 5 (G3, G4, G5) tumor samples from a tissue microarray stained for NRP1. Scale bars, 100 μm. Right panel: summary of NRP1 staining intensity scores across Gleason grades. Scoring scale: no staining (0), low (+1), moderate to high (+2). (b) RNA-sequencing data from the TCGA PRAD cohort comparing NRP1 mRNA expression in patients with tumors of varying Gleason pattern (primary and secondary, leftmost 2 panels), pathological T scores (middle panel) and node status/response to primary therapy (rightmost 2 panels). *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. PR, partial response; SD, stable disease. (c) Kaplan–Meier curves showing relapse-free survival in 498 PCa patients stratified according to the median levels (high versus low) for NRP1 expression (RNA-seq, log2(x+1) RSEM) in the TCGA PRAD cohort. (d) NRP1 expression in TJU post-radiotherapy samples. Each sample is annotated in the colored matrix below the plot. ECE, extra-capsular extension; LNI, lymph node invasion; MET, metastasis; SM, surgical margin; SVI, seminal vesicle invasion. (e) Boxplot showing NRP1 expression in patients positive and negative for BCR. (f) ROC curve for NRP1 expression predicting BCR. (g) Kaplan–Meier curve showing BCR-free survival for NRP1 high and low expression groups.